Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulsed Docetaxel and Concurrent Radiation for NSCLC
NCT00167401Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2002
- Primary completion
- Jun 2007
- Countries
- 1
- Sponsor
- University of Rochester
- Modality
- Small Molecules
- Drugs
- docetaxel
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in non-small cell lung cancer (NSCLC), sponsored by University of Rochester. Primary endpoint: Treatment Efficacy. Started Feb 2002; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Experimental Arm
Induction chemotherapy followed by concurrent chemoradiation
03
Who it enrols
Patients with stage IIIA or IIIB NSCLC, measurable disease, and adequate organ function. Excludes malignant pleural effusion and distant metastasis.
04
Endpoints
Primary
Treatment Efficacy
Secondary
Safety and Side Effects
Quality of Life
Beyond the preview
Go deeper on NCT00167401.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00167401.